Condition: Atopic Dermatitis · Atopic Dermatitis Eczema · Eczema · Sponsor: Inmagene LLC
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Inmagene Site 1 | Lancaster, California, United States | — |
| Inmagene Site 23 | Los Angeles, California, United States | — |
| Inmagene Site 19 | Ocala, Florida, United States | — |
| Inmagene Site 4 | Tampa, Florida, United States | — |
| Inmagene Site 2 | Rolling Meadows, Illinois, United States | — |
| Inmagene Site 6 | Kew Gardens, New York, United States | — |
| Inmagene Site 21 | New York, New York, United States | — |
| Inmagene Site 11 | Woodbury, New York, United States | — |
| Inmagene Site 20 | Charlotte, North Carolina, United States | — |
| Inmagene Site 10 | Fargo, North Dakota, United States | — |
| Inmagene Site 9 | Columbus, Ohio, United States | — |
| Inmagene Site 5 | Mayfield Heights, Ohio, United States | — |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07734415